Hopstem Biotechnology completed the first closing of a Series C financing to advance its iPSC-derived forebrain neural progenitor-cell platform. New investors include Tasly Capital, Haibang Investment and Guangzhou Health Industry Investment, with follow-on support…
Innate Pharma and Sobi entered a licensing partnership for lacutamab in cutaneous T-cell lymphoma (CTCL). Sobi will pay $75 million at closing, with up to $40 million in near-term Sézary syndrome milestones and up…
Innate Pharma appointed Markus Jensen as chief medical officer and an executive-leadership-team member, effective September 1, succeeding Sonia Quaratino. Jensen is an internal successor who joined Innate in 2024 and has served as head…
Silence Therapeutics reported that divesiran met the randomized Phase 2 SANRECO primary endpoint in phlebotomy-dependent polycythemia vera (PV). Clinical response occurred in 88% of divesiran-treated patients versus 19% with placebo, with activity preserved at…
Innovent Biologics and Daiichi Sankyo entered an exclusive agreement for commercialization of VANFLYTA (quizartinib) in China. Innovent will hold sole commercialization rights and lead market promotion, while Daiichi Sankyo retains development, manufacturing and supply…
China’s NMPA accepted Alebund Pharmaceuticals’ new drug application for AP301, a non-absorbed fiber-iron phosphate binder for hyperphosphatemia in maintenance-dialysis patients with chronic kidney disease. The filing is supported primarily by the 474-patient, 52-week RESPOND-1…
Scholar Rock will remove Catalent Indiana from the apitegromab biologics license application after FDA classified the site’s April inspection as Official Action Indicated. FDA review is proceeding with a second U.S. fill-finish facility, and…
A peer-reviewed Blood study combined single-cell multiome profiling with a three-dimensional, N-cadherin-supported culture system, pharmacologic YTHDF2 inhibition and the self-renewal agonist UM729 to expand serially transplantable human long-term hematopoietic stem cells (LT-HSCs) with balanced…
Investigators deeply profiled anti-CD19 CAR-T products and leukapheresis starting material from the phase I/II HD-CAR-1 dose-escalation study. Among 28 treated patients, six achieved responses despite receiving low doses. These low-dose responders were enriched for…
Investigators developed a multiplex prime-editing framework that combines correction of pathogenic T-cell mutations with engineered resistance to commonly used immunosuppressive drugs. Corrected T cells from patients with subcutaneous panniculitis-like T-cell lymphoma selectively expanded under…
